This strategy discriminates among the total population of cancer cells (SmoM2-YFP+/α6-Integrin+ cells), the CSCs (CD34+ cells), and the somatic cells of the bulk of the tumor (CD34− cells). This evidence concerns the gene CD34 and neoplasm.